2024
Overvaluation of shape/weight at posttreatment predicts relapse at 12‐month follow‐up after successful behaviorally‐based treatment of binge‐eating disorder
Grilo C, Ivezaj V, Gueorguieva R. Overvaluation of shape/weight at posttreatment predicts relapse at 12‐month follow‐up after successful behaviorally‐based treatment of binge‐eating disorder. International Journal Of Eating Disorders 2024, 57: 1268-1273. PMID: 38321617, PMCID: PMC11093697, DOI: 10.1002/eat.24141.Peer-Reviewed Original ResearchOvervaluation of shape/weightEating-disorder psychopathologyBinge-eating disorderEating Disorder Examination interviewBeck Depression InventoryWeight loss treatmentClinical overvaluationBinge-eating frequencyDiagnostic specifierBinge eatingNon-abstinenceExamination interviewDepression InventoryShape/weightDepression scoresFollow-upPsychopathologyAbstinenceBingeDepressionClinical implicationsDepression 1PosttreatmentDisordersOvervaluation
2011
Trajectories of Depression Severity in Clinical Trials of Duloxetine: Insights Into Antidepressant and Placebo Responses
Gueorguieva R, Mallinckrodt C, Krystal JH. Trajectories of Depression Severity in Clinical Trials of Duloxetine: Insights Into Antidepressant and Placebo Responses. JAMA Psychiatry 2011, 68: 1227-1237. PMID: 22147842, PMCID: PMC3339151, DOI: 10.1001/archgenpsychiatry.2011.132.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntidepressive AgentsData Interpretation, StatisticalDepressive Disorder, MajorDouble-Blind MethodDuloxetine HydrochlorideFemaleHumansLinear ModelsMalePatient DropoutsPlacebo EffectPsychiatric Status Rating ScalesRandomized Controlled Trials as TopicSelective Serotonin Reuptake InhibitorsSeverity of Illness IndexThiophenesTreatment OutcomeConceptsSelective serotonin reuptake inhibitorsPlacebo-treated patientsComparator selective serotonin reuptake inhibitorsHAM-D scoresClinical trialsAntidepressant treatmentPlacebo responseMajor depressionDouble-blind clinical trialHigh placebo response rateSerotonergic antidepressant treatmentPlacebo response ratesSerotonin reuptake inhibitorsAntidepressant nonrespondersPlacebo armMost patientsAntidepressant respondersMedication risksReuptake inhibitorsSerotonergic antidepressantsResponder statusTreatment responseClinical trajectoriesDepression scoresDepression severity